Attached files
| file | filename |
|---|---|
| EX-99.2 - MEDYTOX QUARTERLY FINANCIAL STATEMENTS - Rennova Health, Inc. | rennova_ex9902.htm |
| EX-23.1 - CONSENT - Rennova Health, Inc. | rennova_ex2301.htm |
| EX-23.2 - CONSENT - Rennova Health, Inc. | rennova_ex2302.htm |
| EX-99.1 - MEDYTOX ANNUAL FINANCIAL STATEMENTS - Rennova Health, Inc. | rennova_ex9901.htm |
| EX-99.3 - UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS - Rennova Health, Inc. | rennova_8k-ex9903.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A
(Amendment No. 1)
CURRENT REPORT PURSUANT
TO SECTION 13 or 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): November 6, 2015
Rennova Health, Inc.
(Exact Name of Registrant as Specified in Its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
| 001-35141 | 68-0370244 |
| (Commission File Number) | (I.R.S. Employer Identification No.) |
| 400 S. Australian Avenue, Suite 800, West Palm Beach, Florida | 33401 |
| (Address of Principal Executive Offices) | (Zip Code) |
| (561) 855-1626 |
| (Registrant’s Telephone Number, Including Area Code) |
| (Former Name or Former Address, if Changed Since Last Report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
EXPLANATORY NOTE
On November 6, 2015, Rennova Health, Inc. (formerly known as CollabRx, Inc.) (the “Company”) filed with the Securities and Exchange Commission (the “SEC”) a Current Report on Form 8-K (“Original Form 8-K”) disclosing, among other things, the completion of the merger of CollabRx Merger Sub, Inc. ("Merger Sub"), a direct wholly owned subsidiary of the Company formed for the purpose of the merger, and Medytox Solutions, Inc. ("Medytox").
The purpose of this amended Current Report on Form 8-K/A is to amend the Original Form 8-K to include the financial statements required by Items 9.01(a) and 9.01(b) of Form 8-K. Except as set forth herein, the Original 8-K remains unchanged.
Item 9.01. Financial Statements and Exhibits.
| (a) | Financial Statements of Business Acquired. |
The financial statements of Medytox required by Item 9.01(a) are filed as Exhibit 99.1 and Exhibit 99.2 to this Current Report on Form 8-K/A and incorporated herein by reference.
| (b) | Pro Forma Financial Information. |
The pro forma financial information of the Company and Medytox required by this Item 9.01(b) is filed as Exhibit 99.3 to this Current Report on Form 8-K/A and is incorporated herein by reference.
| (d) | Exhibits |
| Exhibit No. | Description | ||
| 23.1 | Consent of Green & Company, CPAs. | ||
| 23.2 | Consent of DKM Certified Public Accountants. | ||
| 99.1 | Audited Consolidated Financial Statements of Medytox Solutions, Inc. for the years ended December 31, 2014 and 2013. | ||
| 99.2 | Unaudited Consolidated Financial Statements of Medytox Solutions, Inc. for the three and six months ended June 30, 2015 and 2014. | ||
| 99.3 | Unaudited Pro Forma Condensed Combined Financial Statements. |
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: November 18, 2015 | RENNOVA HEALTH, INC. | |
| By: /s/ Seamus Lagan | ||
| Seamus Lagan | ||
| Chief Executive Officer | ||
| (principal executive officer) |
| 3 |
EXHIBIT INDEX
| Exhibit No. | Description | |
| 23.1 | Consent of Green & Company, CPAs. | |
| 23.2 | Consent of DKM Certified Public Accountants. | |
| 99.1 | Audited Consolidated Financial Statements of Medytox Solutions, Inc. for the years ended December 31, 2014 and 2013. | |
| 99.2 | Unaudited Consolidated Financial Statements of Medytox Solutions, Inc. for the three and six months ended June 30, 2015 and 2014. | |
| 99.3 | Unaudited Pro Forma Condensed Combined Financial Statements. |
| 4 |